Drug Shortage Report for SUPRAX
| Report ID | 204671 |
| Drug Identification Number | 00868981 |
| Brand name | SUPRAX |
| Common or Proper name | Cefixime tablets |
| Company Name | ODAN LABORATORIES LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | CEFIXIME |
| Strength(s) | 400MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 7 tablets and 10 tablets |
| ATC code | J01DD |
| ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2023-09-18 |
| Estimated end date | 2023-11-30 |
| Actual end date | 2023-11-30 |
| Shortage status | Resolved |
| Updated date | 2023-12-01 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | info@odanlab.com Tel.: 1-800-387-9342 Fax: 1-800-329-6326 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2023-12-01 | English | Compare |
| v7 | 2023-11-30 | French | Compare |
| v6 | 2023-11-30 | English | Compare |
| v5 | 2023-11-15 | French | Compare |
| v4 | 2023-11-15 | English | Compare |
| v3 | 2023-09-19 | English | Compare |
| v2 | 2023-09-18 | French | Compare |
| v1 | 2023-09-18 | English | Compare |
Showing 1 to 8 of 8